PROSPECTS FOR USE OF TARGET DRUGS IN NEOADJUVANT CHEMOTHERAPY OF COLORECTAL CANCER METASTASIS IN THE LIVER (REVIEW) (20-22)

DOI:

Дата публикации статьи в журнале: 2020/09/16

Название журнала: Евразийский Союз Ученых — публикация научных статей в ежемесячном научном журнале, Выпуск: 77, Том: 1, Страницы в выпуске: 20-22

Автор: Niyozova Sh.Kh.
, Republican Scientific and Practical Medical Center of Oncology and Radiology of the Ministry of Health of the Republic of Uzbekistan ,

Анотация: To increase the effectiveness of chemotherapy (CT) of metastases of colorectal cancer (CRC) in the liver therapy, targeted drugs are used, usually in combination with standard CT. However, at present, there is not enough clinical research data confirming the effectiveness of a combination of various chemotherapy regimens with drugsinhibitors of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) in conditions of neoadjuvant chemotherapy in this category of patients, which indicates the need for similar studies.

Ключевые слова: colorectal cancer, liver metastases,preoperative chemotherapy,targeted drugs,

Данные для цитирования: Niyozova Sh.Kh. . PROSPECTS FOR USE OF TARGET DRUGS IN NEOADJUVANT CHEMOTHERAPY OF COLORECTAL CANCER METASTASIS IN THE LIVER (REVIEW) (20-22) // Евразийский Союз Ученых — публикация научных статей в ежемесячном научном журнале. Медицинские науки. 2020/09/16; 77(1):20-22.

Скачать в формате PDF

Список литературы: 1.Assessorova Yu.Yu., Kireev G.V., Balenkov O.Yu. The most important modern trends in cancer incidence in different countries (review) // Journal of Theoretical and Clinical Medicine. -2009. -№2. –P.7781. 2.Balenkov O.Yu., Yuldasheva D.Yu., Kireev G.V., Kamyshov S.V. Study of oncological morbidity in the population of Tashkent // Journal of Theoretical and Clinical Medicine. -2007. -N 3. –P.90-92. 22 Евразийский Союз Ученых (ЕСУ) #8(77), 2020 3.Bazin I.S., Mamontov K.G. Modern approaches to chemotherapy in the complex treatment of localized colon cancer // Oncological Coloproctology. -2011. №2. -P.27-36. 4.Chang M.H., Ahn H.K., Lee J. et al. Clinical impact of amphiregulin expression in patients with epidermal growth factor receptor (EGFR) wild-type nonsmall cell lung cancer treated with EGFR-tyrosine kinase inhibitors // Cancer. -2011. –V.117. –P.143–151. 5. Falcone A., Ricci S., Brunetti I. et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest // J. Clin. Oncol. -2007. –V.13. –P.1670–1676. 6.Fedyanin M.Yu., Tryakin A.A., Tyulyandin S.A. Chemotherapy of patients with metastatic colon cancer // Oncological Coloproctology. -2012. -No 2. C.26-34.Chang M.H., Ahn H.K., Lee J. et al. Clinical impact of amphiregulin expression in patients with epidermal growth factor receptor (EGFR) wild-type nonsmall cell lung cancer treated with EGFR-tyrosine kinase inhibitors // Cancer. -2011. –V.117. –P.143–151. 7.Kamishov S.V. Mechanisms of immune disorders in patients with ovarian cancer receiving chemotherapy and their dynamics during immunotherapy // Eurasian Oncological Journal, -2018 -P. 563-576 8.Kamishov S.V. Modern immunopharmacotherapy in the complex treatment of cervical cancer // Bulletin of Science and Education - 2018 -V.2 (6 (42)), -P. 57-61 9.Kamishov S.V., Pulatov D.A., Nishanov D.A., Yuldasheva N.Sh. Influence of the expression level of tumor markers on the results of treatment of patients with cervical cancer who received concomitant immunotherapy // Eurasian Oncological Journal 5 (1), - 2017-P. 68-76 10.Kamishov S.V., Pulatov D.A., Yusupova N.B., Niezova Sh.Kh. The state of immunoreactivity of patients with cervical cancer against the background of extracorporeal immunopharmacotherapy // Bulletin of the National. medical surgeon. center them. N.I. Pirogov 13 (1), -P. 98-102 11. Kamishov S.V., Pulatov D.A.Supportive immunotherapy in complex treatment of patients with oncogynaecological diseases //The scientific heritage - 2017 -V.18 (18), 23-27 12. Kamyshov S.V., Nishanov D.A., Pulatov D.A., Yuldasheva N.S. //Izuchenie markerov apoptoza, proliferacii i angiogeneza u bol'nyh rakom jaichnika, poluchivshih soprovoditel'nuju immunoterapiju [The study of markers of apoptosis, proliferation and angiogenesis in patients with ovarian cancer who received accompanying immunotherapy]. Zlokachestvennye opuholi [Malignant tumors], 1, 84-91 13. Kamyshov S.V., Pulatov D.A., Nishanov D.A., Yuldasheva N.S., Yusupova N.B. Znachimost'ocenki molekuljarno-biologicheskih onkomarkerov v soprovoditel'noj immunoterapii pri rake shejki matki [Significance of the assessment of molecular biological tumor markers in accompanying immunotherapy for cervical cancer]. Onkologija i radiologija Kazahstana [Oncology and radiology of Kazakhstan], 2017 V.2 -P. 45-48 14. Kamyshov S.V., Pulatov D.A., Yuldasheva N.S. Ispol'zovanie metodov gravitacionnoj hirurgii krovi v kompleksnom lechenii bol'nyh rakom jaichnika [The use of gravitational blood surgery methods in the complex treatment of patients with ovarian cancer]. Vestnik Nacional'nogo mediko-hirurgicheskogo centra im. NI Pirogova BBBulletin of the National Medical and Surgical Center after Ni Pirogov], -201712 (1), -P. 52-56Nigri G., Petrucciani N., Ferla F. et al. Neoadjuvant chemotherapy for resectable colorectal liver metastases: what is the evidence? Results of a systematic review of comparative studies // Surgeon. 2015. –V.13. –P.83-90. 15.Nasti G., Piccirillo M.C., Izzo F. et al. Neoadjuvant FOLFIRI+bevacizumab in patients with resectable liver metastases from colorectal cancer: a phase 2 trial // Br. J. Cancer. -2013. –V.108. –P.1566– 1570. 16. Nordlinger B., Sorbye H., Glimelius B. et al. Perioperative chemotherapy with FOLFOX4 and surgery vs. surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup Trial 40983): a randomized controlled trial // Lancet. -2008. –V.371. –P.1007–1016. 17. Petrelli F., Barni S. Anti-EGFR agents for liver metastases. Resectability and outcome with anti-EGFR agents in patients with KRAS wild-type colorectal liver-limited metastases: a meta-analysis // Int. J. Colorectal Dis. -2012. –V.27. –P.997–1004. 18. Pulatov D.A., Ibragimov Zh.M., Kamishov S.V. Comparative assessment of the toxicity of treatment of patients with chemoresistant colorectal cancer // Oncology and Radiology of Kazakhstan -2018 V.44 (2), -P. 58-61 19. Sabanathan D., Eslick G.D., Shannon J. Use of Neoadjuvant Chemotherapy Plus Molecular Targeted Therapy in Colorectal Liver Metastases: A Systematic Review and Meta-analysis // Clin. Colorectal Cancer. 2016. –V.15. –P.e141–e147. 20. Schmoll H.J., Van Cutsem E., Stein A. et al. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making // Ann. Oncol. 2012. –V.23. -N10. –P.2479–2516. 21. Tillyashaikhov M.N., Kamishov S.V. Features of the cellular status of immunity in patients with cervical cancer European science, 2018 No. 5 (37) P.75-79. 22. Tillyashaikhov M.N., Kamishov S.V. Features of the humoral status of immunity in patients with cervical cancer // Materials of the conference International scientific review of the problems and prospects of modern science and education 2018 -p. 84- 87 23. Ye L.C., Liu T.S., Ren L. et al. Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases // J. Clin. Oncol. -2013. –V.31. –P.1931-1938.